Glenmark Prescribed drugs has launched the primary biosimilar of the favored anti-diabetic drug, Liraglutide in India, which is able to decrease the remedy value by roughly 70%. The drug is being marketed underneath the model Lirafit, following an approval from the Drug Controller Normal of India. It’s priced round Rs 100 for the standard dose of 1.2 mg (per day) and will likely be accessible solely underneath prescription, says an organization assertion.
Liraglutide belongs to the category of glucagon-like peptide 1 receptor agonist (GLP-1 RA) medication, which improve glucose-dependent insulin secretion and reduce in applicable glucagon secretion. It has been accepted globally for the administration of kind 2 diabetes mellitus in grownup sufferers in america and European Union.
“With this launch, now we have now ventured into the injectable anti-diabetic market, taking one other vital stride within the diabetes remedy area,” Alok Malik, president and enterprise head ‐ India Formulations, Glenmark Prescribed drugs, stated.
Scientific trials on Liraglutide have demonstrated a number of advantages, together with successfully decreasing glycemic parameters, weight discount, and cardiovascular security in sufferers with kind 2 diabetes mellitus, it provides.
As per the ICMR-INDIAB research carried out between October 2008 and December 2020, the general weighted prevalence of diabetes was 11.4%.
In line with IQVIA gross sales knowledge for the 12‐month interval ending August 2023 (MAT August 2023), the marketplace for GLP-1 RA in India is estimated to be Rs 259 crore, with an annual progress of 108% in opposition to the corresponding interval final 12 months (MAT August 2022).
Liraglutide belongs to the category of glucagon-like peptide 1 receptor agonist (GLP-1 RA) medication, which improve glucose-dependent insulin secretion and reduce in applicable glucagon secretion. It has been accepted globally for the administration of kind 2 diabetes mellitus in grownup sufferers in america and European Union.
“With this launch, now we have now ventured into the injectable anti-diabetic market, taking one other vital stride within the diabetes remedy area,” Alok Malik, president and enterprise head ‐ India Formulations, Glenmark Prescribed drugs, stated.
Scientific trials on Liraglutide have demonstrated a number of advantages, together with successfully decreasing glycemic parameters, weight discount, and cardiovascular security in sufferers with kind 2 diabetes mellitus, it provides.
As per the ICMR-INDIAB research carried out between October 2008 and December 2020, the general weighted prevalence of diabetes was 11.4%.
In line with IQVIA gross sales knowledge for the 12‐month interval ending August 2023 (MAT August 2023), the marketplace for GLP-1 RA in India is estimated to be Rs 259 crore, with an annual progress of 108% in opposition to the corresponding interval final 12 months (MAT August 2022).
